You are here: Industry Insights > Sotrovimab

News List

Primary endpoint met in COMET-TAIL Phase III trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19 WorldPharmaNews
November 16, 2021
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase III trial...
TGA provisionally approves GlaxoSmithKline's COVID-19 treatment: sotrovimab (XEVUDY) firstwordpharma
August 23, 2021
On 20 August 2021, the Therapeutic Goods Administration (TGA), part of the Department of Health, granted provisional approval to GlaxoSmithKline (GSK) Australia Pty Ltd for its COVID-19 treatment - sotrovimab (XEVUDY) - making it the second COVID-19.
Additional COVID-19 treatment for Australia firstwordpharma
August 09, 2021
The Australian Government has secured an initial shipment of over 7,700 doses of the novel monoclonal antibody treatment sotrovimab.
GSK and Vir enter supply deal with European Commission for Covid-19 drug pharmaceutical-technology
July 29, 2021
GlaxoSmithKline and Vir Biotechnology have entered a joint procurement agreement with the European Commission (EC) to deliver up to 220,000 doses of the companies’ experimental drug, sotrovimab, to treat Covid-19.
GSK Singapore and Vir Biotechnology Announce Advance Purchase Agreement with the Government of Singapore for Monoclonal Antibody Sotrovimab (VIR-7831) prnasia
June 30, 2021
GlaxoSmithKline Singapore and Vir Biotechnology announced an agreement with the Government of Singapore for the supply of sotrovimab, an investigational single-dose monoclonal antibody, for the treatment of patients with COVID-19 who do not require ...
FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19 americanpharmaceuticalreview
June 01, 2021
The U.S. FDA issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy sotrovimab for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 ...
UAE approves highly effective new treatment for COVID-19 firstwordpharma
May 31, 2021
The Ministry of Health and Prevention (MoHAP) has approved the emergency use of a highly effective new treatment for COVID-19, becoming the first country in the world to both license and enable immediate patient use.
GSK, Vir's COVID-19 antibody sotrovimab wins FDA nod for emergency use firstwordpharma
May 27, 2021
The FDA on Wednesday granted an emergency-use authorisation to GlaxoSmithKline and Vir Biotechnology's sotrovimab for adults and paediatric patients ages 12 and older who have mild-to-moderate COVID-19 and are at high risk of progressing to severe disease
GSK-Vir’s Covid-19 drug sotrovimab obtains positive EMA opinion pharmaceutical-technology
May 25, 2021
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has issued a positive scientific opinion for GlaxoSmithKline (GSK) and Vir Biotechnology’s sotrovimab (VIR-7831) as early Covid-19 treatment.

Previous page 1 2 Next page